Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RP11-296E3.2 (also known as SNX7 divergent transcript or SNX7-DT) is a novel human-specific long noncoding RNA (lncRNA) that acts as a molecular chaperone for the RNA-binding protein YBX1, thereby promoting the transcription and phosphorylation of STAT3. RP11-296E3.2 is upregulated in metastatic and drug-resistant colorectal cancer and facilitates cancer cell proliferation and metastasis both in vitro and in vivo. Mechanistically, it physically binds to YBX1, enabling YBX1-mediated activation of STAT3 gene expression, which drives colorectal carcinogenesis and cancer progression. Due to its key oncogenic function, RP11-296E3.2 is considered a potential diagnostic and therapeutic target, as well as a clinically relevant biomarker for colorectal cancer[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RP11-296E3.2 (SNX7-DT).